FDA Puts Hold On Adaptive Trials, Wants More Clarity On Basics

FDA would like to slow the escalating momentum behind adaptive clinical trial designs to allow time to craft better working definitions of the new models and build a better base before moving forward, agency officials indicated at a Pharmaceutical Research & Manufacturers of America workshop